Evoq Remedies

Why is Evoq Remedies Ltd falling/rising?

As of 17-Jul, Evoq Remedies Ltd's stock price is Rs. 2.05, unchanged from the previous session, with a year-to-date decline of 35.74% and a one-year drop of 54.34%. The stock has underperformed against the Sensex and is trading below key moving averages, indicating a lack of investor confidence despite a recent increase in trading volume.

As of 17-Jul, Evoq Remedies Ltd's stock price is currently at Rs. 2.05, showing no change from the previous trading session. The stock has experienced significant declines over various periods, with a year-to-date drop of 35.74% and a one-year decrease of 54.34%. Additionally, the stock has hit a new 52-week low of Rs. 1.98 today.<BR><BR>In comparison to the benchmark Sensex, Evoq Remedies has underperformed significantly, with a three-year decline of 85.86% against a 17.36% increase in the Sensex. This stark contrast indicates a lack of investor confidence in the stock, contributing to its falling price.<BR><BR>Despite today's performance showing an outperformance against its sector by 1.41%, the overall trend remains negative as the stock is trading lower than its moving averages across multiple time frames (5-day, 20-day, 50-day, 100-day, and 200-day). However, there has been a notable increase in investor participation, with a delivery volume that rose by 22.95% against the 5-day average, suggesting some interest in the stock despite its overall decline.<BR><BR>In summary, the combination of significant historical losses, underperformance relative to the benchmark, and trading below key moving averages are primary factors contributing to the falling price of Evoq Remedies Ltd.

Which are the latest news on Evoq Remedies?

What does Evoq Remedies do?

Evoq Remedies Ltd is a Micro Cap company in the Trading & Distributors industry, originally founded in 2010 and publicly listed in 2021. It currently reports no sales or profits, with a market cap of INR 7 Cr.

Overview:<BR>Evoq Remedies Ltd operates in the Trading & Distributors industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>Evoq Remedies Ltd was originally incorporated as "Salus Life Science and Research Private Limited" in 2010. The company changed its name to "Evoq Remedies Private Limited" in 2019 and subsequently became a public company, adopting the name "Evoq Remedies Limited" in 2021. There is no sales or profit data reported for the latest quarter.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: INR 7 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A<BR>Industry P/E: 34<BR>Dividend Yield: 0.00%<BR>Debt-Equity: 0.00<BR>Return on Equity: -0.54%<BR>Price-to-Book: 0.16<BR><BR>Contact Details:<BR>Registrar Address: Not available.

How big is Evoq Remedies?

As of 10th June, Evoq Remedies Ltd has a market capitalization of 7.00 Cr, classifying it as a Micro Cap company, with Shareholder's Funds of 44.54 Cr and Total Assets of 50.01 Cr reported as of March 2025. There is no valid financial data available for Net Sales or Net Profit for the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Evoq Remedies Ltd has a market capitalization of 7.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for Net Sales or Net Profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: The latest reporting period is March 2025, with Shareholder's Funds amounting to 44.54 Cr and Total Assets valued at 50.01 Cr.

Who are the peers of the Evoq Remedies?

Evoq Remedies' peers include Parker Agrochem, Devine Impex, Nyssa Corp., Enterprise Intl., Hemo Organic, Mystic Electron., Flora Corporatio, and Worldwide Alumi. Evoq Remedies has Below Average management risk and growth, with a 1-year return of -34.59%, better than Nyssa Corp. but worse than Hemo Organic.

Peers: The peers of Evoq Remedies are Parker Agrochem, Devine Impex, Nyssa Corp., Enterprise Intl., Hemo Organic, Mystic Electron., Flora Corporatio, and Worldwide Alumi.<BR><BR>Quality Snapshot: Excellent management risk is observed at Parker Agrochem and Flora Corporatio, while Average management risk is found at Worldwide Alumi. Below Average management risk is noted for Devine Impex, Nyssa Corp., Evoq Remedies, Enterprise Intl., and the rest. Growth is Average at Parker Agrochem and Average at Worldwide Alumi, while Below Average growth is seen at Devine Impex, Nyssa Corp., Evoq Remedies, Enterprise Intl., and the rest. Good capital structure is present at Parker Agrochem and Flora Corporatio, while Below Average capital structure is noted for Evoq Remedies, Enterprise Intl., and the rest.<BR><BR>Return Snapshot: Hemo Organic has the highest 1-year return at 102.09%, while Nyssa Corp. has the lowest at -37.98%. Evoq Remedies' 1-year return of -34.59% is better than Nyssa Corp.'s but worse than Hemo Organic's. Additionally, the six-month return is negative for Devine Impex, Nyssa Corp., Evoq Remedies, Enterprise Intl., Flora Corporatio, and Worldwide Alumi.

When is the next results date for Evoq Remedies Ltd?

The next results date for Evoq Remedies Ltd is 27 May 2026.

The next results date for Evoq Remedies Ltd is scheduled for 27 May 2026.

How has been the historical performance of Evoq Remedies?

Evoq Remedies has shown significant financial fluctuations, with net sales increasing to 11.76 Cr in March 2025 from 4.05 Cr in March 2024, but down from 20.39 Cr in March 2023. The company reported a cash flow outflow of -14.00 Cr in March 2025, indicating a volatile financial trajectory.

Answer:<BR>The historical performance of Evoq Remedies shows significant fluctuations in its financial metrics over the years.<BR><BR>Breakdown:<BR>Evoq Remedies reported net sales of 11.76 Cr in March 2025, a notable increase from 4.05 Cr in March 2024, but a decline from 20.39 Cr in March 2023. The total operating income mirrored this trend, reaching 11.76 Cr in March 2025, up from 4.05 Cr in the previous year, yet down from 20.39 Cr in March 2023. The total expenditure, excluding depreciation, was 13.99 Cr in March 2025, rising from 5.69 Cr in March 2024, while the operating profit (PBDIT) was slightly positive at 0.18 Cr, down from 0.62 Cr in March 2024 and 2.28 Cr in March 2023. The profit before tax decreased to 0.13 Cr in March 2025 from 0.61 Cr in March 2024, and the profit after tax also fell to 0.09 Cr from 0.45 Cr in the previous year. The company's total assets increased to 50.01 Cr in March 2025 from 36.86 Cr in March 2024, while total liabilities rose to 50.01 Cr from 36.86 Cr. The cash flow from operating activities showed a significant outflow of -14.00 Cr in March 2025, contrasting with a positive inflow of 5.00 Cr in March 2024. Overall, Evoq Remedies has experienced a volatile financial trajectory, with varying sales, profits, and cash flows over the years.

Who are the top shareholders of the Evoq Remedies?

The top shareholders of Evoq Remedies are primarily individual investors, holding 84.74% of shares. Notably, Dhruv Ganji is the largest public shareholder at 11.35%, while promoter Patel Payal Bhumishth holds 6.02%.

The top shareholders of Evoq Remedies include individual investors who hold a significant portion of the company, accounting for 84.74% of the total shares. Among the major shareholders, the highest public shareholder is Dhruv Ganji, who holds 11.35%. Additionally, Patel Payal Bhumishth is the promoter with the highest holding at 6.02%. There are no institutional holdings from mutual funds or foreign institutional investors, and there are no pledged promoter holdings.

Is Evoq Remedies overvalued or undervalued?

As of April 11, 2025, Evoq Remedies is rated as "risky" and overvalued, with a PE ratio of 10.63, negative EV to EBITDA of -6.61, and a Price to Book Value of 0.42, significantly underperforming against peers and the Sensex.

As of 11 April 2025, Evoq Remedies has moved from a grade of "does not qualify" to "risky." The company is currently considered overvalued. Key ratios include a PE ratio of 10.63, an EV to EBITDA of -6.61, and a Price to Book Value of 0.42, which indicate significant concerns regarding profitability and valuation relative to its assets.<BR><BR>In comparison to peers, Evoq Remedies' PE ratio is substantially lower than that of Sun Pharmaceutical Industries Ltd. at 35.25 and Divi's Laboratories Ltd. at 79.33, both of which are categorized as expensive. Additionally, the company's negative EV to EBIT and EV to EBITDA ratios suggest that it is not generating positive earnings, further emphasizing its overvaluation status. Notably, Evoq Remedies has underperformed significantly against the Sensex over the past year, with a stock return of -52.41% compared to the Sensex's 7.55%, reinforcing the notion of its current overvaluation.

What is the technical trend for Evoq Remedies?

As of June 3, 2025, Evoq Remedies shows a neutral technical trend with mixed signals: weekly indicators are mildly bullish while monthly indicators are mildly bearish, reflecting a weak overall trend.

As of 3 June 2025, the technical trend for Evoq Remedies has changed from mildly bearish to sideways. The current technical stance is neutral, with mixed signals across different time frames. The weekly MACD is mildly bullish, while the monthly MACD is mildly bearish, indicating divergence. The weekly RSI is bullish, but the monthly RSI shows no signal, suggesting a lack of momentum in the longer term. Bollinger Bands are bullish on the weekly chart but mildly bearish on the monthly, further reflecting the mixed outlook. Daily moving averages are mildly bearish, which contrasts with the weekly indicators. Overall, the strength of the trend is weak, with the Dow Theory indicating a mildly bullish stance on both weekly and monthly time frames.

Has Evoq Remedies declared dividend?

No Dividend History Available